Zobrazeno 1 - 10
of 411
pro vyhledávání: '"Florence, Dalenc"'
Autor:
Serena Di Cosimo, José Manuel Pérez-García, Meritxell Bellet, Florence Dalenc, Miguel J. Gil Gil, Manuel Ruiz-Borrego, Joaquín Gavilá, Elena Aguirre, Peter Schmid, Frederik Marmé, Joseph Gligorov, Andreas Schneeweiss, Joan Albanell, Pilar Zamora, Duncan Wheatley, Eduardo Martínez de Dueñas, Kepa Amillano, Eileen Shimizu, Miguel Sampayo-Cordero, Javier Cortés, Antonio Llombart-Cussac
Publikováno v:
Breast, Vol 76, Iss , Pp 103761- (2024)
Background: The capsule formulation of CDK4/6 inhibitor palbociclib has reduced solubility at gastric pH > 4.5 and may have decreased activity when used with proton-pump inhibitors (PPI). Herein, we report the effect of PPI on palbociclib capsule act
Externí odkaz:
https://doaj.org/article/d3b96315025744e9a531e42906d8d57a
Autor:
Sylvie Giacchetti, Enora Laas, Thomas Bachelot, Jérome Lemonnier, Fabrice André, David Cameron, Judith Bliss, Sylvie Chabaud, Anne-Claire Hardy- Bessard, Magali Lacroix-Triki, Jean-Luc Canon, Marc Debled, Mario Campone, Paul Cottu, Florence Dalenc, Annabelle Ballesta, Frederique Penault-Llorca, Bernard Asselain, Elise Dumas, Fabien Reyal, Paul Gougis, Francis Lévi, Anne-Sophie Hamy
Publikováno v:
EBioMedicine, Vol 104, Iss , Pp 105141- (2024)
Summary: Background: Circadian rhythms regulate cellular physiology and could influence the efficacy of endocrine therapy (ET) in breast cancer (BC). We prospectively tested this hypothesis within the UNIRAD adjuvant phase III trial (NCT01805271). Me
Externí odkaz:
https://doaj.org/article/9f42a221348c45659c954d1962e5d5fe
Autor:
Gauthier Glemarec, Jean-Louis Lacaze, Bastien Cabarrou, Richard Aziza, Eva Jouve, Slimane Zerdoud, Eleonora De Maio, Carole Massabeau, Maxime Loo, Vincent Esteyrie, Mony Ung, Florence Dalenc, Francoise Izar, Ciprian Chira
Publikováno v:
Breast, Vol 69, Iss , Pp 424-427 (2023)
Externí odkaz:
https://doaj.org/article/b09eb453b47647b2a44b0002bcea4806
Autor:
Florian Martinet-Kosinski, Sébastien Lamy, Eric Bauvin, Florence Dalenc, Charlotte Vaysse, Pascale Grosclaude
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-9 (2023)
Abstract Non-menopausal women with breast cancer treated with chemotherapy are at intermediate risk of post-treatment amenorrhea and decreased fertility. Although they should receive appropriate information, studies until now show that this is inadeq
Externí odkaz:
https://doaj.org/article/335b838449e54b4287a6adb1236f6382
Autor:
Gauthier Glemarec, Jean-Louis Lacaze, Bastien Cabarrou, Richard Aziza, Eva Jouve, Slimane Zerdoud, Eleonora De Maio, Carole Massabeau, Maxime Loo, Vincent Esteyrie, Mony Ung, Florence Dalenc, Francoise Izar, Ciprian Chira
Publikováno v:
Breast, Vol 67, Iss , Pp 102-109 (2023)
Purpose: Local ablative treatment (LAT) is increasingly combined with systemic therapy in oligometastatic breast cancer (OMBC), without a high-level evidence to support this strategy. We evaluated the addition of LAT to systemic treatment in terms of
Externí odkaz:
https://doaj.org/article/a63ea51182e14f5598d6d0214ad99b4b
Autor:
Fabien Moinard-Butot, Caroline Saint-Martin, Carole Pflumio, Matthieu Carton, William Jacot, Paul-Henri Cottu, Véronique Diéras, Florence Dalenc, Anthony Goncalves, Marc Debled, Anne Patsouris, Marie-Ange Mouret-Reynier, Laurence Vanlemmens, Marianne Leheurteur, George Emile, Jean-Marc Ferrero, Isabelle Desmoulins, Lionel Uwer, Jean-Christophe Eymard, Bianca Cheaib, Coralie Courtinard, Thomas Bachelot, Michaël Chevrot, Thierry Petit
Publikováno v:
Breast, Vol 63, Iss , Pp 54-60 (2022)
Purpose: Trastuzumab-emtansine (T-DM1), as well as lapatinib plus capecitabine were proven effective in two Phase III studies, following first-line trastuzumab plus a taxane. The introduction of dual HER2 blockade by trastuzumab and pertuzumab as fir
Externí odkaz:
https://doaj.org/article/91f75990af2445a0a8def40ce2143a62
Autor:
Lisa A. Carey, Delphine Loirat, Kevin Punie, Aditya Bardia, Véronique Diéras, Florence Dalenc, Jennifer R. Diamond, Christel Fontaine, Grace Wang, Hope S. Rugo, Sara A. Hurvitz, Kevin Kalinsky, Joyce O’Shaughnessy, Sibylle Loibl, Luca Gianni, Martine Piccart, Yanni Zhu, Rosemary Delaney, See Phan, Javier Cortés
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-7 (2022)
Abstract Patients with triple-negative breast cancer (TNBC) who relapse early after (neo)adjuvant chemotherapy have more aggressive disease. In the ASCENT trial, sacituzumab govitecan (SG), an antibody-drug conjugate composed of an anti-Trop–2 anti
Externí odkaz:
https://doaj.org/article/531a8b18c5434564aa5198960edea038
Autor:
Florian Martinet-Kosinski, Sébastien Lamy, Eric Bauvin, Florence Dalenc, Charlotte Vaysse, Pascale Grosclaude
Publikováno v:
Frontiers in Public Health, Vol 11 (2023)
IntroductionToo few women with invasive breast cancer are informed of the risk of hypofertility after chemotherapy. However, this risk can be prevented by offering gamete preservation by a specialized team. We believe that if more women were informed
Externí odkaz:
https://doaj.org/article/d57ff5ec04e44bd090157a883392e07a
Autor:
Renaud Sabatier, Cécile Vicier, Séverine Garnier, Arnaud Guille, Nadine Carbuccia, Nicolas Isambert, Florence Dalenc, Marie Robert, Christelle Levy, Jihane Pakradouni, José Adelaïde, Max Chaffanet, Patrick Sfumato, Emilie Mamessier, François Bertucci, Anthony Goncalves
Publikováno v:
Molecular Oncology, Vol 16, Iss 10, Pp 2057-2070 (2022)
The phosphatidylinositol‐3‐kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway is frequently activated in HER2‐negative breast cancer and may play a role in taxane resistance. The phase IB/II TAKTIC trial (NCT01980277) has shown that
Externí odkaz:
https://doaj.org/article/703ca5faef324c5b808393f820024f09
Autor:
François Poumeaud, Anna Fontanier, Jérémie Dion, Quentin Mathevet, Olivier Cointault, Emmanuelle Uro-Coste, Céline Marty, Florence Dalenc, Pierre Girardie, Anaïs Rataboul
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Externí odkaz:
https://doaj.org/article/1a0d48fd610c4e89b30fd7fcdb52c471